Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLUE bluebird bio	$4.97	$4.49	$3.20 ▼ $28.60	$48.67M	0.27	432,189 shs	N/A
CRGX CARGO Therapeutics	$4.50 +5.1%	$4.23	$3.00 ▼ $25.45	$207.50M	0.47	551,616 shs	976,584 shs
SOPH SOPHiA GENETICS	$3.03 +4.1%	$2.98	$2.58 ▼ $5.63	$202.06M	1.03	54,170 shs	35,614 shs
URGN UroGen Pharma	$5.00 +3.3%	$9.12	$3.42 ▼ $20.70	$230.54M	0.66	730,432 shs	3.92 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLUE bluebird bio	-0.20%	-0.60%	+25.57%	+29.84%	-72.55%
CRGX CARGO Therapeutics	+0.94%	+4.39%	-0.93%	+12.63%	-77.47%
SOPH SOPHiA GENETICS	-2.35%	+2.11%	-3.96%	-6.13%	-41.68%
URGN UroGen Pharma	+19.80%	+15.51%	-57.95%	-49.58%	-63.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLUE bluebird bio	3.1216 of 5 stars	3.1	5.0	0.0	2.4	1.7	1.3
CRGX CARGO Therapeutics	2.2652 of 5 stars	2.9	0.0	0.0	3.2	1.7	1.3
SOPH SOPHiA GENETICS	2.8453 of 5 stars	3.4	5.0	0.0	3.6	0.0	0.6
URGN UroGen Pharma	4.0477 of 5 stars	4.4	1.0	4.5	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLUE bluebird bio	2.25	Hold	$44.60	797.38% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	233.33% Upside
SOPH SOPHiA GENETICS	2.75	Moderate Buy	$6.80	127.42% Upside
URGN UroGen Pharma	2.88	Moderate Buy	$23.14	356.47% Upside

Current Analyst Ratings Breakdown

Latest BLUE, URGN, SOPH, and CRGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	URGN UroGen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00
5/23/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00
5/22/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/13/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/8/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/29/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/28/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/28/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
4/17/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$22.00 ➝ $16.00
3/31/2025	BLUE bluebird bio	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $8.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$9.84 per share	N/A
SOPH SOPHiA GENETICS	$67.17M	2.97	N/A	N/A	N/A	∞
URGN UroGen Pharma	$91.87M	2.54	N/A	N/A	($2.78) per share	-1.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	8/14/2025 (Estimated)
CRGX CARGO Therapeutics	-$98.15M	-$4.62	N/A	N/A	N/A	N/A	-38.16%	-33.94%	8/11/2025 (Estimated)
SOPH SOPHiA GENETICS	-$78.98M	-$1.00	N/A	N/A	N/A	-110.71%	-55.06%	-38.33%	8/5/2025 (Estimated)
URGN UroGen Pharma	-$102.24M	-$3.18	N/A	N/A	N/A	-129.11%	N/A	-47.94%	8/12/2025 (Estimated)

Latest BLUE, URGN, SOPH, and CRGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	URGN UroGen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/6/2025	Q1 2025	SOPH SOPHiA GENETICS	-$0.21	-$0.26	-$0.05	-$0.26	$16.76 million	$17.78 million
3/10/2025	Q4 2024	URGN UroGen Pharma	-$0.69	-$0.80	-$0.11	-$0.80	$25.25 million	$24.57 million
3/4/2025	Q4 2024	SOPH SOPHiA GENETICS	-$0.23	-$0.23	N/A	-$0.23	$17.71 million	$17.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLUE bluebird bio	0.37	0.51	0.33
CRGX CARGO Therapeutics	N/A	18.94	18.95
SOPH SOPHiA GENETICS	0.12	3.80	3.59
URGN UroGen Pharma	4.77	9.00	8.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLUE bluebird bio	87.43%
CRGX CARGO Therapeutics	93.16%
SOPH SOPHiA GENETICS	31.59%
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
BLUE bluebird bio	1.40%
CRGX CARGO Therapeutics	2.92%
SOPH SOPHiA GENETICS	4.88%
URGN UroGen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
CRGX CARGO Therapeutics	116	46.11 million	45.39 million	N/A
SOPH SOPHiA GENETICS	520	66.69 million	62.19 million	Not Optionable
URGN UroGen Pharma	200	46.11 million	22.26 million	Optionable

BLUE, URGN, SOPH, and CRGX Headlines

Recent News About These Companies

URGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 3 at 5:00 PM | globenewswire.com

Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN) - Join by July 28, 2025 - Contact Levi & Korsinsky

June 3 at 4:00 PM | accessnewswire.com

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

June 3 at 3:33 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman

June 3 at 2:16 PM | investing.com

Class Action Lawsuit Filed Against UroGen Pharma Ltd. (URGN) - Recover Losses - Contact Levi & Korsinsky Before July 28, 2025

June 3 at 2:15 PM | accessnewswire.com

July 28, 2025 Deadline Approaching: Join Class Action Against UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky

June 3 at 1:15 PM | accessnewswire.com

UroGen Pharma (NASDAQ:URGN) Price Target Cut to $10.00 by Analysts at Oppenheimer

June 3 at 11:24 AM | marketbeat.com

Levi & Korsinsky Notifies UroGen Pharma Ltd. (URGN) Investors - Lead Plaintiff Deadline on July 28, 2025

June 3 at 11:15 AM | accessnewswire.com

July 28, 2025 Deadline Approaching: Join Class Action Against UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky

June 3 at 10:30 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

June 3 at 10:00 AM | accessnewswire.com

URGN ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against UroGen Pharma Ltd. - July 28, 2025 Deadline

June 3 at 9:30 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN

June 3 at 9:00 AM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 28, 2025 Deadline

June 3 at 7:55 AM | accessnewswire.com

Investor Alert: Deadline Approaching to Join UroGen Pharma Ltd. (URGN) Class Action - Contact Levi & Korsinsky

June 3 at 7:30 AM | accessnewswire.com

URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

June 3 at 7:00 AM | accessnewswire.com

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

June 3 at 3:31 AM | uk.finance.yahoo.com

Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

June 3 at 3:31 AM | tmcnet.com

UroGen Pharma Ltd. (URGN) Launches uTRACT Registry to Track JELMYTO Use in UTUC

June 3 at 1:33 AM | insidermonkey.com

Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025 - Contact Levi & Korsinsky

June 2 at 10:15 PM | accessnewswire.com

UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd.

June 2 at 9:00 PM | globenewswire.com

URGN LAWSUIT ALERT: Levi & Korsinsky Notifies UroGen Pharma Ltd. Investors - Lead Plaintiff Deadline July 28, 2025

June 2 at 5:42 PM | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
By Leo Miller | May 13, 2025
View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
Don’t Take Dick’s Sporting Goods Seriously? Big Mistake
By Thomas Hughes | May 29, 2025
View Don’t Take Dick’s Sporting Goods Seriously? Big Mistake

BLUE, URGN, SOPH, and CRGX Company Descriptions

bluebird bio NASDAQ:BLUE

$4.97 0.00 (0.00%)

As of 06/2/2025

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CARGO Therapeutics NASDAQ:CRGX

$4.50 +0.22 (+5.14%)

Closing price 04:00 PM Eastern

Extended Trading

$4.50 +0.00 (+0.11%)

As of 04:33 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

SOPHiA GENETICS NASDAQ:SOPH

$3.03 +0.12 (+4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 -0.01 (-0.33%)

As of 04:04 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

UroGen Pharma NASDAQ:URGN

$5.00 +0.16 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$4.92 -0.08 (-1.50%)

As of 05:18 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time